Clinical trial
A Phase 1, Multicenter, Open-Label, Dose-Escalation/Consolidation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Orally Administered JBI-778 in EGFR Mutated Lung Cancer Patients With or Without Brain Metastasis, Isocitrate Dehydrogenase (IDH) Mutated WHO Grade 3/4 Recurrent Glioma and Adenoid Cystic Carcinoma (ACC)
NCT07755397 is registered in ClinicalTrials.gov with Jubilant Therapeutics India Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-Label, Dose-Escalation/Consolidation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Orally Administered JBI-778 in EGFR Mutated Lung Cancer Patients With or Without Brain Metastasis, Isocitrate Dehydrogenase (IDH) Mutated WHO Grade 3/4 Recurrent Glioma and Adenoid Cystic Carcinoma (ACC)
- Lead sponsor
- Jubilant Therapeutics India Limited
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 26, 2024
- Completion date
- April 30, 2028
- Enrollment
- 30 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
adenoid cystic carcinoma metastatic, adenoid cystic carcinoma of the head and neck, nsclc patients with egfr activating mutation